Global Osteoarthritis Drugs Market to Hit $17.7 Billion by 2031: A Comprehensive Outlook

The global osteoarthritis drugs market has been experiencing significant growth, driven by a rising incidence of osteoarthritis, an aging population, and advancements in pharmaceutical research. In 2022, the market was valued at US$ 8.6 billion and is projected to grow at a CAGR of 8.5% from 2023 to 2031, reaching a valuation of US$ 17.7 billion by the end of 2031.

Download to explore critical insights from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=47571

Analyst Viewpoint

The growing prevalence of osteoarthritis and the increasing geriatric population are primary drivers of the market. Pharmaceutical companies are actively exploring innovations, such as asymptomatic drugs and injectable resiniferatoxin, to address the growing demand for effective and preventive care solutions. These advancements align with efforts to improve the quality of life for osteoarthritis patients and address unmet medical needs, paving the way for substantial growth in the market.

Market Introduction

Osteoarthritis, commonly referred to as degenerative joint disease, primarily affects joints such as the neck, knees, hips, lower back, and fingers. It gradually progresses, leading to moderate to severe pain, reduced mobility, and diminished quality of life. Populations with low physical activity levels or higher body mass index (BMI) are particularly susceptible.

Pain Management Solutions

Common treatments include oral, topical, and parenteral pain medications, with research indicating these solutions can reduce pain by approximately 30%. However, adverse side effects associated with nonsteroidal anti-inflammatory drugs (NSAIDs), such as cardiovascular risks, have raised concerns and highlighted the need for safer, more effective alternatives.

Personalized Medicine

The concept of personalized medicine is gaining traction, emphasizing the role of biomarkers in crafting tailored treatment plans. This trend aligns with a growing preference for precision therapies, further fueling market growth.

Visit our report to explore critical insights and analysis - https://www.transparencymarketresearch.com/osteoarthritis-drugs-market.html

Market Drivers

1. Growth in Osteoarthritis Incidence

The prevalence of osteoarthritis is increasing due to lifestyle factors, such as rising obesity rates and sedentary behaviors. Obesity exerts additional pressure on joints, accelerating the deterioration of cushion joints.

• CDC Data: In May 2022, the CDC reported a rise in obesity prevalence from 30.5% to 41.9% between 2019 and 2020 in the U.S., particularly among individuals aged 20-59. This trend directly correlates with a higher incidence of osteoarthritis.

1. Aging Population

The global geriatric population is expected to constitute 16% of the total population by 2050, as per the United Nations. Aging leads to musculoskeletal changes, increasing the risk of osteoarthritis. A 2022 study published by PubMed Central identified osteoarthritis as the leading cause of disability in older adults, emphasizing the urgent need for effective treatments.

Regional Insights

North America

North America accounted for the largest market share in 2022 and is expected to maintain its dominance through 2031.

• U.S. Statistics: Approximately 32.5 million Americans are affected by osteoarthritis, according to the National Public Health Agenda for Osteoarthritis.
• Canada also exhibits a high prevalence, with over 4 million cases reported in 2021 by Arthritis Society Canada.

Europe

Europe's market is driven by a high incidence of osteoarthritis, with over 54 million individuals affected in Western Europe. The preference for joint replacement surgeries further bolsters the market.

Asia Pacific

The growing geriatric population and increasing obesity rates contribute to the region's market growth. Rising awareness and healthcare infrastructure advancements in countries like China and India are creating lucrative opportunities for market players.

Competitive Landscape

Key players in the osteoarthritis drugs market are investing heavily in research and development (R&D) to strengthen their portfolios and enhance patient outcomes.

Notable Developments

1. Sorrento Therapeutics: Published positive Phase 1b trial data for resiniferatoxin (RTX) in September 2020. RTX addresses patients unresponsive to opioids.
2. GlaxoSmithKline: Launched Voltaren in the U.S. in 2020.
3. Novartis: Secured FDA approval in September 2021 for LNA043, a first-in-class treatment for osteoarthritis.
4. Alkem Laboratories: Gained regulatory approval for StemOne, an off-the-shelf cell therapy, in 2022.

Leading Companies

• Horizon Pharma plc
• Pfizer Inc.
• Sanofi
• Anika Therapeutics, Inc.
• Bioventus, Inc.

Market Segmentation

By Drug Class

• Corticosteroids
• NSAIDs & Others
• Viscosupplementation Agents

By Route of Administration

• Oral
• Parenteral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Conclusion

The global osteoarthritis drugs market is poised for substantial growth, driven by demographic trends, lifestyle changes, and innovative pharmaceutical advancements. While challenges such as side effects of NSAIDs persist, the focus on personalized medicine and novel drug development offers promising solutions. Stakeholders are well-positioned to capitalize on emerging opportunities, addressing the unmet needs of osteoarthritis patients worldwide.

Examine key highlights and takeaways from our Report in this sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=47571

Explore Latest Research Reports:

• Veterinary Molecular Diagnostics Market () - The global industry was valued at USD 543.9 million in 2022. It is estimated to grow at a CAGR of 7.9% from 2023 to 2031, reaching USD 1.1 billion by the end of 2031.
• Cancer Supportive Care Drugs Market () - The global industry was valued at USD 14.3 billion in 2022. It is projected to grow at a CAGR of 1.7% from 2023 to 2031, reaching more than USD 16.7 billion by the end of 2031.
• Genome Editing Market () - The global industry was valued at USD 5.5 billion in 2022. It is projected to advance at a CAGR of 13.9% from 2023 to 2031, reaching more than USD 17.5 billion by the end of 2031.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com    
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube